Association of TNF-α polymorphism with prediction of response to TNF blockers in spondyloarthritis and inflammatory bowel disease: a meta-analysis. (November 2013)

• Record Type: Journal Article
• Authors: Tong, Qiang; Zhao, Liang; Qian, Xiao-Di; Zhang, Lan-Ling; Xu, Xia; Dai, Sheng-Ming; Cai, Qing; Zhao, Dong-Bao
• Is Part Of: Pharmacogenomics. Volume 14:Number 14(2013)
• Page Start: 1691
• Page End: 1700
• Publication Date: 2013-11
• Subjects: inflammatory bowel disease -- meta-analysis -- prediction -- spondyloarthritis -- TNF blocker -- TNF-α-308 polymorphism -- TNF-α-857 polymorphism; Pharmacogenomics -- Periodicals; 615.1
• DOI: 10.2217/pgs.13.146
• Languages: English
• ISSNs: 1462-2416

Abstract

Aim: To explore whether TNF- α promoter -308 A/G and -857 C/T polymorphisms have an association with responsiveness to TNF blockers in spondyloarthritis and inflammatory bowel disease.Methods: A meta-analysis was performed. Pooled odds ratios (ORs) and 95% CIs were calculated.Results: Six relevant studies with a total of 211 spondyloarthritis patients and 392 inflammatory bowel disease patients were included. The results showed that the common allele (G and C, respectively) showed a better responsiveness than the minor allele (A and T, respectively). The -308 G/G genotype (OR: 2.31; 95% CI: 1.36–3.91; p = 0.002) and -857 C/C genotype (OR: 3.66; 95% CI: 1.35–9.92; p = 0.01) responded better to therapy, which was different from the results of some studies included.Conclusion: Individuals with the TNF- α-308 G allele and -857 C allele showed better anti-TNF-α treatment responses than those with the TNF- α-308 A allele and -857 T allele. The -308 G/G genotype and -857 C/C genotype are predictors of good response. Original submitted 30 May 2013; Revised submitted 25 July 2013